Private Equity
Viela Bio, which spun off from MedImmune, the global biologics research and development arm of AstraZeneca, has raised $250 million in funding. The investors included Boyu Capital, 6 Dimensions Capital, Hillhouse Capital, Temasek and Sirona Capital. AstraZeneca will remain the largest minority shareholder of Viela Bio. Based in Gaithersburg, Maryland, Viela Bio will focus on developing medicines for severe autoimmune diseases.
1 min read · 28 February 2018
London-based venture firm Kindred Capital has closed its debut seed fund at 80 million pounds (about $110 million). Kindred focuses on European tech companies. The firm gives entrepreneurs the opportunity to co-own the fund that invested in their business.
4 min read · 28 February 2018
1 min read · 28 February 2018
2 min read · 27 February 2018
Leawood Venture Capital has raised $25 million for its new fund, according to an SEC filing. The Leawood, Kansas-based venture firm invests in early and expansion stage businesses.
1 min read · 27 February 2018
South San Francisco-based Senti Biosciences, a synthetic biology company, has closed $53 million in funding. New Enterprise Associates led the round with participation from 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital and LifeForce Capital.
1 min read · 27 February 2018
Nomad Health, an online marketplace for healthcare jobs, has raised $12 million in Series B financing. Polaris Partners led the round with participation from other investors that included First Round Capital, RRE Ventures and .406 Ventures. In addition to the funding, Brian Chee, a managing partner at Polaris, will be joining Nomad Health’s board of directors.
1 min read · 27 February 2018
Cambridge, Massachusetts-based Generation Bio, a developer of genetic medicines, has secured $100 million in Series B financing. Fidelity Management & Research Company led the round with participation from Invus, Deerfield Management Company, Casdin Capital, Foresite Capital and Leerink Partners’ affiliates.
1 min read · 27 February 2018
Palo Alto, California-based Spring Discovery, a machine learning-based drug discovery platform provider, has raised $4.25 million in seed funding, according to a post by its CEO. The investors included General Catalyst, First Round, Sam Altman and Sea Lane Ventures.
1 min read · 26 February 2018
PenderFund Capital Management Ltd has held the first close of a new fund earmarked for investments in mid-stage private and public technology companies primarily located in Western Canada and Western United States. The amount raised by Pender Technology Inflection Fund I was not disclosed. The fund will be co-managed by Maria Pacella, Pender's senior vice president, private equity, and David Barr, the firm's president and CEO. It will target opportunities for developing "fundamental technologies," such as the convergence of health and technology, as well as data-driven technologies. Vancouver-based Pender is a mutual funds manager.
3 min read · 26 February 2018
